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Early application of Met-RANTES ameliorates chronic allo- Although substantial stride has been made over the
graft nephropathy. past few years in increasing the short-term success of
Background. Initial insults to kidney allografts, character- kidney transplantation, the rate of long-term graft attri-ized by infiltration of mononuclear inflammatory cells, contrib-
tion due to chronic allograft nephropathy has remainedute to chronic allograft nephropathy. Chemokines such as
constant [1]. A number of alloantigen dependent andRANTES (regulated upon activation, normal T cell expressed)
are thought to be responsible for the recruitment and activation non-alloantigen dependent factors have been suggested
of infiltrating cells. The present study investigated whether to be involved in the development of the process [2, 3].
early application of Met-RANTES, a chemokine receptor an- Among these factors, initial insults to the graft aftertagonist that blocks the effects of RANTES, can protect renal
transplantation are correlated to late renal allograft dete-allografts from long-term deterioration.
Methods. Fisher (F344) rat kidneys were orthotopically rioration and failure [4]. Despite the application of cyclo-
transplanted into Lewis recipients and treated with cyclospo- sporine A (CsA), the grafts undergo early episodes of
rine A (1.5 mg/kg/day) for the first 10 days following trans- clinically inapparent acute rejection, mediated by an in-
plantation, together with either Met-RANTES at 40 g/day,
flux of inflammatory mononuclear cells into graft tissues,200 g/day or vehicle for the first 7 days. Animals were har-
which primarily consist of T lymphocytes and monocytes/vested at 2 and 28 weeks after transplantation for histologic,
immunohistologic and molecular analysis. macrophages [2, 5, 6]. This early infiltration of immuno-
Results. Met-RANTES treatment reduced the infiltration of cytes may provide the pathologic continuity or link be-
lymphocytes and macrophages in allografts at 2 weeks after tween acute rejection and subsequently evolving chronictransplantation, accompanied by decreased mRNA expression
graft deterioration [6–8].of interleukin (IL)-2, IL-1, tumor necrosis factor- (TNF-)
and RANTES. At post-transplantation week 28, Met-RANTES The recruitment of inflammatory cells from peripheral
treatment at high and low doses reduced urinary protein excre- circulation into transplanted kidneys and their activation
tion and significantly ameliorated glomerulosclerosis, intersti- involve the actions of chemokines, a large superfamily
tial fibrosis, tubular atrophy, intimal proliferation of graft arter-
of structurally related cytokines [9–11]. RANTES (regu-ies and mononuclear cell infiltration. However, creatinine
lated upon activation, normal T cell expressed) is a po-clearance was not influenced by Met-RANTES. Furthermore,
Met-RANTES suppressed the mRNA expression of trans- tent chemotactic agent that is a member of the CC che-
forming growth factor- (TGF-) and platelet-derived growth mokine family, [12–13]. In vitro, it activates T cells,
factor-B (PDGF-B). monocytes, natural killer cells, basophils, and eosinophilsConclusions. Blockade of chemokine receptors by Met-
by binding to their CC chemokine receptors [14]. RANTESRANTES diminishes early infiltration and activation of mono-
expression is regulated by proinflammatory stimuli suchnuclear cells in the grafts, and thus reduces the pace of chronic
allograft nephropathy. as interleukin-1 (IL-1) or tumor necrosis factor-
(TNF-) [15–16], and its production has been reported
for a variety of cell types, including T lymphocytes, endo-
thelial cells, fibroblasts, mesangial cells, and tubular epi-
thelial cells [15–21].
In vivo, RANTES is suggested to be one of the keyKey words: kidney transplantation, chronic rejection, chemokine, Met-
RANTES, rats, leukocyte infiltration. players in the pathogenesis of acute renal allograft rejec-
tion. Its accumulation on inflamed renal tubuli and endo-Received for publication June 18, 2001
thelial cells provides directional signals for the circulatingand in revised form August 7, 2001
Accepted for publication September 10, 2001 leukocytes to undergo diapedesis and extravasation,
which thus underlie the acute injury process [22–24]. 2002 by the International Society of Nephrology
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In addition, RANTES expression is further increased IM; Hoffmann-la Roche AG, Grenzach-Wyhlen, Ger-
many) on the first postoperative day. Animals wereduring the initial episodes of acute renal rejection, and
peaks at the intermediate phase between early injury treated with low-dose Cyclosporine A (1.5 mg/kg/day,
SC; Novartis GmbH, Nu¨rnberg, Germany) over the firstand chronic deterioration [7]. This may facilitate the
ensuing cellular infiltrate that predisposes the grafts to ten days after transplantation to overcome an initial epi-
sode of acute rejection. The contralateral native kidneychronic rejection. Indeed, kidney-grafted patients af-
fected by chronic transplant dysfunction had significantly was removed on the tenth postoperative day.
higher plasma levels of RANTES than those of controls
Experimental design[25]. In parallel to the up-regulation of RANTES expres-
sion, massive cellular infiltrates positive for chemokine Met-RANTES was dissolved in water, adjusted to
0.9% sodium chloride, and injected into transplantedreceptors of RANTES were identified at the interstitial
areas of chronic allograft nephropathy [26]. Hence, animals once daily intravenously (IV) at the assigned
dose.RANTES may potentially play an important intermedi-
ary role between the early and late phase of chronic Transplanted animals were divided into three groups
according to the treatment dosage of Met-RANTES. Forrejection, and may serve as a link in inducing chronic
changes. the first seven days after transplantation, rats (N  15/
group) received either 40 g/day Met RANTES (low-Met-RANTES is human RANTES with the addition
of a single methionine residue, and this compound is a dose Met-RANTES), 200 g/day Met-RANTES (high-
dose Met-RANTES), or vehicle (controls). Grafts ofreceptor antagonist that has been shown to antagonize
chemokine receptors in rats [27–29]. In a monocyte at- randomly selected animals of the different groups were
harvested at two weeks post-transplant (N  5/group),tachment assay on microvascular endothelium under
physiological flow conditions, Met-RANTES completely and at 28 weeks post-transplant (N  10/group), respec-
tively.inhibited the RANTES-mediated arrest of monocytes
onto the endothelium [22]. In a rat model of acute renal
Functional measurementsrejection, Met-RANTES reduced vascular and tubular
damage by blocking immunocyte arrest and recruitment Every four weeks, body weight was measured and 24-
hour urine samples were collected using metabolic cages[22]. However, whether blockade of the effects of
RANTES in the early phase after transplantation with with a urine-cooling system. Quantitative urine protein
was nephelometrically determined. Serum and urine cre-Met-RANTES protects renal grafts from long-term dete-
rioration remains illusive. Therefore, the present study atinine levels as well as hormones were measured and
creatinine clearance was calculated at the end of theinvestigated the effects of Met-RANTES on the occur-
rence and progression of chronic nephropathy allograft study.
in an established rat model at cellular and molecular
Histologylevels.
For histology, kidney tissues were fixed in 4% buffered
formalin, embedded in paraffin and stained with either
METHODS
hematoxylin/eosin or periodic acid-Schiff (PAS). Glo-
Animals merulosclerosis was defined as a collapse of capillaries,
adhesion of the obsolescent segment of Bowman’s cap-Naive inbred male Fisher (F344, RT1v1) and male
Lewis (Lew, RT1) rats (Charles River, Sulzfeld, Ger- sule and entrapment of hyaline in the mesangium [30].
At least 200 glomeruli were counted per kidney sec-many), weighing 200 to 250 g, were kept under standard
conditions and fed with rat chow and water ad libitum. tion and the proportion of sclerosed to total glomeruli
was expressed as percentage (glomerulosclerosis index).All experiments were approved by a governmental com-
mittee on animal welfare. Glomerulopathy, tubular atrophy, interstitial fibrosis
and vascular intimal proliferation were quantified ac-
Kidney transplantation cording to the Banff 1997 classification [30] and scored
0 to 3, respectively to produce numerical coding (0 toUnder ketamine (Ketamin, 100 mg/kg IP; CP-Pharma,
Burgdorf, Germany) and xylacine (Rompun, 10 mg/kg 12) of kidney damages. Histology was evaluated in a
blinded fashion by two independent observers.IP; Bayer, Leverkusen, Germany) anesthesia the left
donor kidney was removed, cooled and positioned ortho-
Immunohistochemistrytopically into the recipient. Donor and recipient renal
artery, vein and ureter were anastomosed end-to-end For immunohistology, cryostat sections (4 m) were
fixed in acetone, air-dried and stained individually withwith 10-0 Prolene sutures. No ureteral stent was used.
To overcome infectious complications due to operation primary monoclonal mouse-derived antibodies against
monocytes/macrophages (ED1) and CD5 T-lympho-rats received Cephtriaxone (Rocephin; 20 mg/kg/day,
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cytes (OX19; Serotec Camon Labor-Service GmbH,
Wiesbaden, Germany). After incubation with primary
antibody, sections were incubated with rabbit anti-mouse
IgG and thereafter with the alkaline phosphatase anti-alka-
line phosphatase (APAAP) complex (DAKO A/S, Ham-
burg, Germany). Cells staining positive were counted
and expressed as cells per field of view (cells/fv). At least
20 fields of view per section and per specimen were
evaluated at 400 magnification.
RNase protection assay
Total RNA was extracted using Trizol reagent (Gibco)
according to manufacturer’s instructions. Intragraft mRNA
expression specific for transforming growth factor-1 Fig. 1. Changes in 24-hour urinary protein excretion during the course
of the experiment in animals treated with low-dose Met-RANTES (),(TGF-1), IL-1, IL-1, IL-2, IL-5, IL-6, IL-10, inter-
high-dose Met-RANTES (), and vehicle (). Data are mean  SEMferon- (INF-), TNF- and glyceraldehyde-3-phos- from 10 rats in each group. *P 	 0.05 as compared to control at the
phate dehydrogenase (GAPDH; Riboquant Multi-Probe same time point.
template set; Pharmingen, Becton Dickinson GmbH,
Hamburg, Germany) was determined by RNase protec-
tion assay using the In vitro Transcription Kit and RPA
mide. Cytokine cDNA was semiquantitated by densito-Kit (Pharmingen) as described previously [31]. Briefly,
metric comparison with -actin (internal control) from32P-labeled antisense riboprobes were synthesized with
the same sample after the positive image was digitizedthe use of T7 RNA polymerase transcription in the pres-
by video for computerized densitometry. The results areence of [32P]UTP. Radiolabeled antisense riboprobes
given as the ratio of intensity of growth factors to -actinwere then hybridized with 10 g of total RNA extracted
mRNA.from cultured cells at 56
C overnight. After hybridiza-
tion, RNase A  T1 were added to digest unhybridized Statistical analysis
RNA and duplex RNA hybrids were separated by elec-
Data are presented as mean  SEM. Parametric datatrophoresis on a 5% polyacrylamide gel. Intensities of
were compared using one-way analysis of variancethe protected bands were quantified by a phosphorim-
(ANOVA), followed by multiple pair-wise comparisonsaging analyzer (Fuji-BAS 1500; Fuji, Du¨sseldorf, Ger-
according to the Newman-Keuls test. Nonparametricmany) and the ratios of the investigated genes to
data were tested using the Kruskal-Wallis one-way anal-GAPDH (internal control) were calculated.
ysis of ranks. Discrete data were compared using Chi
Reverse transcriptase-polymerase chain reaction square test. A P value of less than 0.05 was considered
significant.Intragraft mRNA expression of RANTES was deter-
mined by reverse transcriptase-polymerase chain reac-
tion (RT-PCR). Briefly, cDNA was synthesized from RESULTS
isolated RNA by reverse transcription (RT) using the
Effects of Met-RANTES on late changes ofSuperScript preampification system as described by
allograft nephropathythe manufacturer (Gibco/BRL, Karlsruhe, Germany).
Functional measurements. Twenty weeks after trans-PCR was performed on cDNA for the amplification of
plantation, an obvious disparity of urinary protein ex-RANTES and -actin using the primers (sense and anti-
cretion emerged between Met-RANTES treated andsense) designed according to published sequence [7].
control animals, with the latter developing higher pro-One microliter from RT reaction was taken for PCR,
teinuria (P 	 0.05; Fig. 1). The difference was mostwhich was performed in PCR buffer (Qiagen GmbM,
prominent at week 28 (41.7  6.3 mg/24 h in controls;Hilden, Germany) using 0.2 mmol/L/L of each deoxy-
24.8 6.3 mg/24 h in low-dose Met-RANTES and 26.2nucleoside triphosphates, 1 mol/L/L of both primers
7.7 mg/24 h in high-dose Met-RANTES; Fig. 1). There(Eurogentec, Ko¨ln, Germany), and 2.5 U thermus Aqua-
were no significant differences in urinary protein excre-ticus (Taq) DNA polymerase (Dianova). A Perkin-
tion between low-dose and high-dose Met-RANTESElmer Thermal Cycler (Model 9600; Perkin-Elmer, Nor-
treated animals during the entire follow-up period. Se-walk, CT, USA) was used for amplification allowing 30
rum creatinine levels and creatinine clearance did notto 35 cycles for each primer.
differ significantly between the groups at the end of theThe amplified PCR product was identified by electro-
phoresis on 1.5% agarose gel stained with ethidium bro- follow-up: creatinine clearance 0.38  0.03 mL/min/100
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Fig. 2. Photomicrographs of periodic acid-
Schiff (PAS) staining (a-f ) and immunohisto-
chemical staining with anti-ED1 mAb (g, h)
in renal allografts harvested at week 28 post-
transplantation. Overviews of minor (Met-
RANTES treated, a) and severe (vehicle
treated, b) deterioration of graft tissue; nor-
mal (Met-RANTES treated, c) and sclerotic
(vehicle treated, d) glomeruli; normal (Met-
RANTES treated, e) and proliferative (vehi-
cle treated, f) artery intima; slight (Met-
RANTES treated, g) and intense (vehicle
treated, h) macrophage infiltration.
g body wt in controls versus 0.37  0.04 mL/min/100 g reduced degree of glomerulopathy (P 	 0.05, Table 1).
Most glomeruli in Met-RANTES treated animals werebody wt in low-dose Met-RANTES, and 0.36 0.03 mL/
min/100 g body wt in high-dose Met-RANTES. of normal size with only minor hypercellularity and pa-
tent capillary loops (Fig. 2c), while those in controls wereHistology and immunohistology. In comparison to
controls, treatment with Met-RANTES independent of more markedly hypertrophied, with focal and segmental
proliferation (Fig. 2d). Nevertheless, the degree of glo-dose significantly ameliorated signs of chronic allograft
nephropathy in terms of glomerulosclerosis, interstitial merulosclerosis and glomerulopathy was comparable be-
tween animals treated with higher and lower dosage offibrosis, tubular atrophy, intimal proliferation of graft
arteries and mononuclear cell infiltration during the ob- Met-RANTES.
(b) Interstitial fibrosis, tubular atrophy and intimal pro-servation period (Fig. 2 a, b).
(a) Glomerulosclerosis and glomerulopathy. By 28 liferation. Along with ameliorated glomerular injury, ar-
teries appeared relatively normal in Met-RANTESweeks, glomerular sclerosis was significantly lower in
Met-RANTES treated animals (22.4  2.1% in low- treated animals (Fig. 2e), with only focal ballooning of
endothelial cells or medial vacuolization. In addition,dose Met-RANTES, and 23.1  2.4% in high-dose Met-
RANTES) as compared to controls (36.8  4.1%, P 	 only minor, nonspecific tubular changes were observed
in grafts of both treatment groups, and interstitial fibrosis0.05; Table 1). Similarly, Met-RANTES resulted in a
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Table 1. Histological evaluation of allograft damages at week 28 post-transplantation
Glomerulopathy Tubular atrophy Interstitial fibrosis
Percentage of Vasculopathy Total Banff
Groups (number) sclerotic glomeruli Grades 2–3 % positive % score
Control (N  10) 36.73.4% 7/10 (70%) 5/10 (50%) 6/10 (60%) 4/10 (40%) 5.20.8
Low-dose Met-RANTES
(N  10) 22.42.0%a 3/10 (30%)b 1/10 (10%)b 2/10 (20%)b 1/10 (10%) 2.70.6a
High-dose Met-RANTES
(N  10) 21.72.3%a 2/10 (20%)b 0/10 (0%)b 2/10 (20%)b 0/10 (0%) 2.30.5a
aP 	 0.05 as compared with controls using Kruskal-Wallis one-way analysis
bP 	 0.05 as compared with controls using Chi square test
was weak. By contrast, sections of allografts from con-
trols demonstrated more severe interstitial fibrosis, tubu-
lar atrophy, and intimal proliferation of the arteries (Fig.
2f). Some cortical arteries contained mild intimal prolif-
eration (	20% of vessel luminal cross-section), while
some had more than 50 percent of luminal occlusion
due to neointimal expansion. Thus, animals from both
treatment groups demonstrated a reduced Banff score as
compared to the controls (P 	 0.05, Table 1). Although
animals treated with high-dose Met-RANTES tended to
have less severe tubular and vascular changes than those
with the low-dose, the difference did not reach statistical
significance. Additionally, the degree of interstitial fi-
brosis did not significantly differ between low- and high-
dose Met-RANTES treated animals (Table 1).
(c) Mononuclear cell infiltration. At week 28, infiltra-
tion of CD5-positive T-lymphocytes and ED1-positive
monocytes/macrophages was immunohistochemically de-
tected in graft tissues of all recipients (Fig. 2 g, h). Mono-
nuclear cells in interstitial areas, spreading from perivas-
cular to periglomerular areas, diffusely infiltrated grafts
from controls. Lymphocytes surrounded the Bowman’s
capsules, while only monocytes/macrophages could be
detected within the glomerular tuft. By contrast, grafts
from animals treated with low-dose or high-dose Met-
RANTES had a relatively circumscript infiltration pat-
tern with a significantly lower number of lymphocytes
(P 	 0.05) and macrophages (P 	 0.05) distributing
Fig. 3. Immunohistochemical evaluation of CD5-positive () andprimarily around vessels (Fig. 3A). Furthermore, the
ED1-positive () cellular infiltration in renal allografts 28 weeks (A;intensity of lymphocytic infiltration as well as that of
N  10/group) and 2 weeks (B; N  5/group) after transplantation.
macrophages was similar in both treatment groups inde- Data are mean  SEM. *P 	 0.05 vs. vehicle-treated animals.
pendent of the dosage used (P  0.05; Fig. 3A).
Growth factor and cytokine mRNA levels. RNase pro-
tection assay showed that Met-RANTES treated recipi-
treatment and control groups in terms of IL-2, IL-1,ents and controls differed in intragraft TGF- and
IFN- and TNF-mRNA expression in renal grafts har-PDGF-B mRNA expression, which contrasted with a
vested at week 28 (data not shown).homogenous expression of GAPDH mRNA (Fig. 4A).
Body weight and mean arterial blood pressure. No dif-As shown in Figure 5, Met-RANTES treatment reduced
ferences were observed in terms of body weight betweenTGF- mRNA expression in allografts by 40% as com-
Met-RANTES treated animals and controls during thepared to controls (P	 0.05). Likewise, PDGF-B mRNA
course of the experiment (body wt at the time of harvest-expression was 1.9- to twofold higher in controls than in
ing: 451 18 g in controls vs. 455 19 g in low-dose Met-Met-RANTES treated animals. (Fig. 5, P 	 0.01). On
the other hand, we discerned no difference between RANTES, and 460  23 g in high-dose Met-RANTES).
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Fig. 4. Representative experiments of RNase
protection assay (A) for TGF-, PDGF-B
chain, IL-1, TNF-, and IL-2 mRNA expres-
sion, and RT-PCR assay (B) for RANTES
mRNA expression. Lane 1, control; lane 2,
low-dose Met-RANTES treated; lane 3, high-
dose Met-RANTES treated.
Likewise, mean arterial blood pressure (MABP) of Met- In parallel, the number of ED1-positive macrophages
was significantly reduced in Met-RANTES treated recip-RANTES treated animals did not significantly differ
from controls (MABP 86.5  7.2 mm Hg in controls vs. ients (P 	 0.05, Fig. 3B).
Cytokine mRNA expression. We further evaluated the81.3 6.2 mm Hg in low-dose Met-RANTES and 89.5
8.3 mm Hg in high-dose Met-RANTES). activation of infiltrating immunocytes by measuring the
mRNA expression of lymphocyte-derived IL-2 as well
Effects of Met-RANTES on infiltrates early as macrophage-derived TNF- and IL-1. In parallel
after transplantation to the intensity of mononuclear cell infiltration, IL-2,
TNF- and IL-1mRNA levels at two weeks after trans-Cellular infiltration. Intragraft infiltrates at day 14
plantation were most pronounced in controls, and wereafter transplantation were examined using immunohisto-
chemical staining for lymphocytes and macrophages. A significantly reduced by Met-RANTES (P 	 0.05; Fig.
6). In contrast, IFN- expression was not influenced bylarge number of CD5-positive lymphocytes infiltrated
control grafts, distributing throughout the interstitium Met-RANTES (P  0.05).
Similarly, RANTES mRNA expression, evaluated bywithout encountering the glomeruli. On the other hand,
grafts from Met-RANTES treated recipients had signifi- RT-PCR, was lower in Met-RANTES treated animals
(P 	 0.05; Fig. 4B). Although high-dose Met-RANTEScantly less lymphocytic infiltration (P 	 0.05; Fig. 3B).
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Fig. 5. RNase protection assay analysis of TGF- (A) and PDGF-B
chain (B) mRNA expression in renal allografts 28 weeks after trans-
plantation. Data are mean  SEM from 10 rats in each group. *P 	
0.05 vs. vehicle-treated animals; §P 	 0.01 vs. vehicle-treated animals.
treatment tended to reduce RANTES mRNA levels to
a greater extent than low-dose treatment, the difference
did not reach statistical significance (P  0.05; Fig. 7).
DISCUSSION
Treatment with Met-RANTES, a chemokine receptor
antagonist, has been demonstrated to prevent acute renal
transplant rejection by blocking the recruitment of
mononuclear cells [22]. However, whether a short course
of Met-RANTES can affect the progression of chronic
allograft nephropathy remained unclear. The present
study demonstrated that early administering of Met- Fig. 6. RNase protection assay analysis of IL-2 (A), IL-1 (B), TNF-
(C) mRNA expression in renal allografts 2 weeks after transplantation.RANTES after transplantation attenuated the progres-
Data are mean  SEM from 5 rats in each group. *P 	 0.05 vs. vehicle-sion of chronic renal allograft rejection by preventing treated animals.
the development of functional and pathological features
of renal graft deterioration, including proteinuria, trans-
plant arteriosclerosis, tubular atrophy, glomerular hy-
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lagen-induced arthritis [36], and airways inflammation
[37]. The mechanisms of action of Met-RANTES, herein,
can be explained by in vitro findings that Met-RANTES
inhibits the chemotactic function of RANTES by block-
ing chemokine receptors on mononuclear cells [26, 27].
In addition, monocyte attachment assays on microvascu-
lar endothelium under physiological flow conditions have
demonstrated that Met-RANTES may act in part by
preventing the shear-resistant arrest and subsequent re-
cruitment of mononuclear cells induced by RANTES [22].
Our study further demonstrated that reduction of cel-
lular infiltrates at two weeks after transplantation by
Met-RANTES was linked to an obvious decrease in in-
Fig. 7. RT-PCR analysis of RANTES mRNA expression in renal allo- terstitial infiltration of macrophages and lymphocytes,grafts 2 weeks after transplantation, expressed as the ratios of the
as well as a marked improvement in glomerulosclerosisdensitometry of RANTES mRNA to -actin mRNA. Data are mean
SEM from 5 rats in each group. *P 	 0.05 vs. vehicle-treated animals. and interstitial fibrosis, at the late post-transplantation
phase. This further confirms that the intensity of mono-
nuclear cell infiltration in the early post-transplantation
phase predisposes the occurrence of chronic graft damage.
pertrophy and glomerulosclerosis. Moreover, we further In addition, Met-RANTES inhibited the activation
revealed that the long-term beneficial effects of Met- and recruitment of T-cells and macrophages, as the ex-
RANTES on the transplants were associated with dimin- pression of proinflammatory mediators, such as IL-1,
ishing graft immunocyte infiltration and activation in the IL-1, TNF-, IFN- and IL-2 two weeks after trans-
early post-transplantation phase. plantation was reduced in treated animals.
With the advent of cyclosporine A, the incidence of It has been suggested that the cytokines produced
lethal acute renal rejection has markedly been reduced, by mononuclear cells in the early post-transplantation
but the reversible acute rejection, characterized by early period provide a molecular basis for the ensuing damage
leukocyte infiltration and elaboration of inflammatory and fibrosis of the grafts [6, 38–40]. The net effect of
cytokines, still exists [2, 5, 6]. Clinically, the occurrence such processes is atrophy of tubular cells, interstitial fi-
of reversible acute rejection episodes is associated with brosis, and loss of renal function [6]. In addition, IL-1
inferior graft survival rates [32, 33]. Hence, acute revers- and TNF- are up-regulated in a number of fibrotic dis-
ible rejection is considered to be a significant risk factor eases. The early involvement of these cytokines has also
for chronic rejection. Our data support this position by been demonstrated in some animal models of fibrosis in
showing that control animals, treated with CsA only, which anti-TNF- and anti-IL-1 antibodies inhibited the
had an extensive mononuclear cell infiltration in the in- ensuing fibrotic response [41, 42]. Hence, inhibition of
terstitial areas of the grafts early after transplantation, T-cell and macrophage activation by early application
and later developed chronic allograft nephropathy. of Met-RANTES in our study may underlie the long-
Studies on the sequential cellular and molecular kinet- term beneficial effects on the allografts.
ics in chronically rejecting renal allografts of rats sug- In our study, allografts of treated animals revealed
gested that early infiltration and activation of T cells and less extensive fibrosis and tubular atrophy than controls.
monocytes/macrophages may provide a cellular basis for This was accompanied by a reduced expression of TGF-
the continuity between early reversible rejection and late and PDGF-B in the respective grafts. PDGF is likely to
deterioration of the grafts [7, 34]. In our study, massive be a critical event in fibroblast proliferation in vitro [43]
infiltration of CD5-positive T-lymphocytes, as well as and in vivo [44], and has been associated with the devel-
ED1-positive macrophages, was observed throughout opment of chronic allograft nephropathy [45]. Addition-
the interstitial areas in control grafts at two weeks after ally, TGF- can induce a significant increase of the mito-
transplantation. The number and extent of infiltrates at genic effect of PDGF [46], and contribute primarily to
this time were markedly reduced by early application of the enhancement of collagen production in fibroblasts by
Met-RANTES. This is in agreement with the previous promoting collagen synthesis and inhibit its degradation
finding in acute renal allograft rejection models, showing [47]. The concomitant elevation of TGF- and PDGF
that Met-RANTES suppressed the recruitment of in- production in the control kidneys revealed their coordi-
flammatory cells into the grafts [22]. In addition, it also nating effect on fibrogenesis, whereas Met-RANTES
has been demonstrated that Met-RANTES decreases treatment inhibited the expression of both factors proba-
the accumulation of T cells and monocytes/macrophages bly by deactivating the infiltrating immunocytes during
the intermediate period, and thus diminished the ongo-at disease sites of crescentic glomerulonephritis [35], col-
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ing fibrogenesis. In support of our findings, a single ad- for this discrepancy. In addition, the present study has
highlighted the mechanisms by which Met-RANTES actsministration of CTLA4Ig during the early post-trans-
plantation period prevented the development of late on chronic allograft nephropathy on the basis of reduc-
tion of leukocyte infiltration and activation. However, itchanges of chronic allograft nephropathy [48].
RANTES has been proposed to play an important also is possible that Met-RANTES interferes with the
induction of the alloreactive response. Hence, furtherintermediary role in the sequential cytokine dynamics
between early and late phase of chronic allograft nephro- studies are needed to evaluate donor-specific immune
reaction of Met-RANTES treated subjects.pathy [7]. RANTES induces the production of proin-
flammatory cytokines during the early phase, which
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